Indication

Polymyalgia rheumatica

Polymyalgia rheumatica is a systemic inflammatory rheumatic disorder that predominantly affects adults aged 50 years and older. Read more about Polymyalgia rheumatica

101 drugs 75 manufacturers

Advertisement

Drugs that treat it

Common Polymyalgia rheumatica therapies.

Showing 37–45 of 101 drugs

KEVZARA (sarilumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·RHEUMATOID ARTHRITIS·+2
Sanofi-Aventis U.S.

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Actavis Pharma

PREDNISONE

GLUCOCORTICOSTEROIDS·PULMONARY TUBERCULOSIS·+67
Hikma Pharmaceuticals USA

KEVZARA (sarilumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·RHEUMATOID ARTHRITIS·+2
Sanofi-Aventis U.S.

PREDNISONE

PULMONARY TUBERCULOSIS·+67
Lannett Company

PREDNISONE

PULMONARY TUBERCULOSIS·+67
NOVITIUM PHARMA

PREDNISOLONE

GLUCOCORTICOSTEROIDS·TRICHINOSIS·+59
PHARMACEU ASSOC
Filter & compare in the drug finder →Opens the drug finder with Polymyalgia rheumatica preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Polymyalgia rheumatica.

Polymyalgia rheumatica is a systemic inflammatory rheumatic disorder that predominantly affects adults aged 50 years and older.

It is clinically defined by subacute, bilateral aching pain and severe morning stiffness lasting longer than 45 minutes, localized primarily to the shoulder girdles, pelvic girdles, and neck.

Pathophysiologically, the condition involves periarticular inflammation characterized by bursitis, tenosynovitis, and synovitis, frequently accompanied by marked elevations in acute-phase reactants such as erythrocyte sedimentation rate and C-reactive protein, and it is closely associated with giant cell arteritis.

Personalize your experience

Follow Polymyalgia rheumatica and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it